NABI-IGIV 10%
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for NABI-IGIV 10%, covering 2012-03-26 to 2012-03-26. Get the full timeline:
Most recent: Clinical Trial Update: Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD) [Phase 3]